Florence is a company.
Florence has raised $36.0M across 1 funding round.
Key people at Florence.
Florence was founded by Aniq Rahman (CEO and Founder).
Florence has raised $36.0M in total across 1 funding round.
Key people at Florence.
Florence Healthcare is a SaaS platform that automates clinical trial operations, focusing on site-facing tools to streamline workflows for research sites, pharmaceutical sponsors, and contract research organizations (CROs).[1][4][6] It solves key bottlenecks in clinical trials, such as paper-based auditing and document management, reducing delays that cost sponsors $600,000–$8 million per day and addressing a $10 billion industry pain point by digitizing processes like eBinder for instant access.[1][4] The platform serves clinical research ecosystems, with early adopters including University of California San Francisco, Mt. Sinai, and Sloan Kettering, and has shown 150% month-over-month usage growth since its January launch, alongside partnerships with Pfizer and top-5 pharmas.[1][4]
Florence Healthcare emerged from the Advanced Technology Development Center’s (ATDC) Signature portfolio, launching in January with a $1.7 million seed round led by Bee Partners, Bessemer Venture Partners, Dartmouth’s Green D Angel Fund, and healthcare entrepreneur Will Crawford.[1][6] Founders identified inefficiencies at clinical trial sites—historically underserved by sponsor-focused software—where manual processes created logjams in data access and therapy launches.[1] Early traction included securing agreements with major institutions like UCSF, Mt. Sinai, and Sloan Kettering’s PCCTC Cancer Research Center ahead of funding, validating its site-centric approach amid peaking competition for top trial sites.[1]
Florence rides the shift to site-centric clinical trials, fueled by post-COVID remote operations, intense site competition, and regulatory pressures for faster therapy delivery.[1][4] Timing aligns with 2025 trends where sponsors enhance site-facing strategies to cut delays and costs, as manual inefficiencies persist despite sponsor-side automation.[4] Market forces like daily trial costs and a growing demand for intuitive SaaS in a $10B pain-point space favor Florence, influencing the ecosystem by enabling sponsors like Pfizer to scale globally and CROs to boost capacity.[1][4][6] It sets a standard for collaborative platforms, reducing risks and accelerating innovations in drug/device development.
Florence is poised to dominate clinical trial tech with SiteLink's AWS expansion and proven ROI, targeting further integrations and global site adoption.[6] Trends like AI-driven workflows and decentralized trials will amplify its edge, potentially capturing more of the inefficient site network as sponsors prioritize quantifiable speed and savings.[4] Its influence may evolve into an industry standard, powering faster patient access to therapies while scaling via pharma partnerships—building on seed momentum to redefine trial efficiency.[1][4][6]
Florence was founded by Aniq Rahman (CEO and Founder).
Florence has raised $36.0M in total across 1 funding round.
Florence's investors include AXA Strategic Ventures, Nauta Capital.
Florence has raised $36.0M across 1 funding round. Most recently, it raised $36.0M Series B in May 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2022 | $36.0M Series B | AXA Strategic Ventures, Nauta Capital |
